The University of Chicago Header Logo

Connection

Richard Schilsky to Precision Medicine

Back to Details
This is a "connection" page, showing publications Richard Schilsky has written about Precision Medicine.
Richard Schilsky
Connection Strength
5.628
Precision Medicine
  1. 'Strategic' development of precision cancer medicine in the United States. Mol Oncol. 2021 07; 15(7):1747-1749.
    View in: PubMed
    Score: 0.501
  2. Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. J Oncol Pract. 2019 11; 15(11):575-583.
    View in: PubMed
    Score: 0.440
  3. Implementing Precision Medicine in Community-Based Oncology Programs: Three Models. J Oncol Pract. 2019 06; 15(6):325-329.
    View in: PubMed
    Score: 0.426
  4. The evidence framework for precision cancer medicine. Nat Rev Clin Oncol. 2018 03; 15(3):183-192.
    View in: PubMed
    Score: 0.393
  5. Innovative clinical trials for development of personalized cancer medicine. Mol Oncol. 2015 May; 9(5):933-4.
    View in: PubMed
    Score: 0.324
  6. Implementing personalized cancer care. Nat Rev Clin Oncol. 2014 07; 11(7):432-8.
    View in: PubMed
    Score: 0.304
  7. Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 2014; 61-9.
    View in: PubMed
    Score: 0.298
  8. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Educ Book. 2013; 118-25.
    View in: PubMed
    Score: 0.278
  9. Personalized cancer medicine - a strategy to counteract an increasing cancer challenge. Mol Oncol. 2012 Apr; 6(2):109-10.
    View in: PubMed
    Score: 0.263
  10. Using patient-initiated study participation in the development of evidence for personalized cancer therapy. Clin Cancer Res. 2011 Nov 01; 17(21):6651-7.
    View in: PubMed
    Score: 0.257
  11. Clinical trials in the era of personalized oncology. CA Cancer J Clin. 2011 Nov-Dec; 61(6):365-81.
    View in: PubMed
    Score: 0.257
  12. Tumor heterogeneity as the foundation of personalized cancer treatment. Semin Oncol. 2011 Apr; 38(2):171-2.
    View in: PubMed
    Score: 0.247
  13. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov. 2010 05; 9(5):363-6.
    View in: PubMed
    Score: 0.231
  14. Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients. Oncotarget. 2025 Mar 12; 16:140-162.
    View in: PubMed
    Score: 0.162
  15. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Jul 11; 15(1):5837.
    View in: PubMed
    Score: 0.155
  16. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar; 8:e2300615.
    View in: PubMed
    Score: 0.151
  17. Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. J Clin Oncol. 2021 04 01; 39(10):1165-1184.
    View in: PubMed
    Score: 0.122
  18. Accelerating anticancer drug development - opportunities and trade-offs. Nat Rev Clin Oncol. 2018 12; 15(12):777-786.
    View in: PubMed
    Score: 0.105
  19. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25.
    View in: PubMed
    Score: 0.084
  20. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. 2015 Jun 10; 6(16):14139-52.
    View in: PubMed
    Score: 0.082
  21. Integrating biomarkers in colorectal cancer trials in the West and China. Nat Rev Clin Oncol. 2015 Sep; 12(9):553-60.
    View in: PubMed
    Score: 0.082
  22. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015 Aug; 26(8):1791-8.
    View in: PubMed
    Score: 0.082
  23. American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol. 2013 Dec 01; 31(34):4362-70.
    View in: PubMed
    Score: 0.074
  24. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
    View in: PubMed
    Score: 0.060
  25. Refocusing the war on cancer: the critical role of personalized treatment. Sci Transl Med. 2010 Apr 21; 2(28):28cm13.
    View in: PubMed
    Score: 0.058
  26. Incorporating data from multiple ongoing trials for Bayesian two-stage phase II single-arm studies. Clin Trials. 2025 Dec; 22(6):667-675.
    View in: PubMed
    Score: 0.042
  27. The Porto European Cancer Research Summit 2021. Mol Oncol. 2021 10; 15(10):2507-2543.
    View in: PubMed
    Score: 0.032
  28. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019 10; 574(7776):127-131.
    View in: PubMed
    Score: 0.028
  29. Challenges and approaches to implementing master/basket trials in oncology. Blood Adv. 2019 07 23; 3(14):2237-2243.
    View in: PubMed
    Score: 0.027
  30. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 05; 25(5):751-758.
    View in: PubMed
    Score: 0.027
  31. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367.
    View in: PubMed
    Score: 0.023
  32. WIN Consortium--challenges and advances. Nat Rev Clin Oncol. 2011 Mar; 8(3):133-4.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.